Mr. Ahmad Doroudian reports
BETTERLIFE PHARMA ENGAGES MARKET MAKER
Betterlife Pharma Inc. has engaged Integral Wealth Securities Ltd. to provide market-making services in accordance with the policies of the Canadian Securities Exchange.
Pursuant to the terms of the agreement, Integral will provide market-making services intended to maintain an orderly trading market for the common shares in the capital of the company on the CSE. Integral will trade the company's securities on the CSE with the objective of supporting liquidity and maintaining reasonable market depth. Integral shall not become an investor or attempt to influence the market price of the common shares.
In consideration for the services, the company will pay Integral a monthly fee of $7,000, plus applicable taxes. The engagement is for an initial term of three months, expected to start on Nov. 20, 2026, and may be terminated by either party upon 30 days written notice before the initial term. Unless terminated during the initial term, the agreement will continue month to month thereafter.
"Our engagement of Integral represents another step in our ongoing efforts to enhance the trading environment for our shareholders and support an orderly and liquid market for the Betterlife's shares," said Doug Drysdale, executive chairman of Betterlife. "We believe that improving market liquidity and trading efficiency is an important part of building shareholder confidence as we continue to advance on clinical developments of BETR-001"
Integral is an independent firm and is not related to the company or any of its directors or officers. Neither Integral nor its principals have any direct or indirect interest in the securities of the company, or any right or intent to acquire such an interest, other than as may arise in the ordinary course of providing market-making services. Integral is located at 181 University Ave., Suite 1600, Toronto, Ont., M5H 3M7 and can be reached at 416-203-2000 or info@integralwealth.com.
The engagement is subject to applicable regulatory requirements and the policies of the CSE.
About BETR-001
BETR-001 is a non-hallucinogenic derivative of 2-bromo-lysergic acid diethylamide (2-Br-LSD) in development for the preventive treatment of chronic cluster headache and chronic migraine. The company holds a granted U.S. composition-of-matter patent covering BETR-001. BETR-001 is an investigational product and has not been approved by any regulatory authority.
The company makes no medical, treatment or health benefit claims about the company's proposed products. The U.S. Food and Drug Administration, Health Canada, or other similar regulatory authorities have not evaluated claims regarding BETR-001 or other programs of the company. The efficacy of such products has not been confirmed by approved research. There is no assurance that BETR-001 or other programs of the company can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If the company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the company's performance and operations.
About Betterlife Pharma Inc.
Betterlife Pharma is an emerging biotechnology company primarily focused on developing and commercializing BETR-001 to treat various neurological disorders, such as chronic cluster headache and chronic migraine.
We seek Safe Harbor.
© 2026 Canjex Publishing Ltd. All rights reserved.